Apollomics Inc (APLM)
Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oncology therapies designed to engage the immune system and target molecular pathways involved in cancer growth. The company’s pipeline includes Vebreltinib (APL-101), an oral and highly selective c-Met inhibitor being evaluated in Phase 2 trials for non-small cell lung cancer and other solid tumors with MET dysregulation. Other candidates include APL-102, a small-molecule multi-tyrosine kinase inhibitor in Phase 1 testing, and APL-122, which is being studied in Phase 1 dose-escalation trials for cancers within the brain. Apollomics also has immuno-oncology programs that include APL-501, APL-502, and APL-801. Founded in 2015, the company is based in Foster City, California.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-APLM
|
$26.27
|
54.7% Upside
|
Bargain
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 13, 2026
|
4.2x
|
37.289 M
|
34.656 M
|
1.7%
|
24.4%
|
-149.4
|
94.8%
|
